Prerna Mewawalla, M.D., outlines six AI roles in myeloma care

Mewawalla's list comes as only 19% of community oncologists use AI predictive models, according to the interview. She worked with J&J on the index and specializes in multiple myeloma and AL amyloidosis, which grounds her perspective in day-to-day care rather than general AI speculation. The six uses she describes are not futuristic: ambient documentation is already in her practice, and tools such as OpenEvidence already return referenced answers. What stands out is the division of labor she assumes—AI drafts and flags, but the physician reviews. She still checks every note, and the order-placing feature she expects would leave orders unsigned for her review. That caution may shape how quickly such tools move from pilot to routine use in community oncology, where patient volumes are high and trial tracking is difficult.